Press release
Heart Failure Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight
"Heart Failure Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Heart Failure Pipeline Report: https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years.
• Heart Failure companies working in the treatment market are Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment
• Emerging Heart Failure therapies in the different phases of clinical trials are- TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.
• In May 2025, BioCardia announced the enrollment of the first participant in its randomized, double-blind, placebo-controlled Phase III CardiAMP HF II trial, evaluating its autologous cell therapy for ischemic heart failure. The enrollment occurred at BayCare Morton Plant Hospital in Clearwater, Florida, U.S. The 250-patient, multicenter study is designed to assess a single administration of CardiAMP therapy in patients with ischemic HF with reduced ejection fraction (HFrEF), who are on guideline-directed medical therapy and have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) levels.
• In May 2025, Medera Inc., a clinical-stage biopharmaceutical company developing next-generation therapies for cardiovascular diseases, announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF trial of the adeno-associated virus-based gene therapy candidate SRD-002 for heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress.
• In April 2025, Emory University School of Medicine in the U.S. began enrolling participants for BioCardia's Phase III CardiAMP HF II trial, evaluating the CardiAMP Cell Therapy Product for the treatment of ischemic heart failure. The study is focused on patients with reduced ejection fraction and elevated cardiac stress markers.
• In April 2025, An independent Data Safety Monitoring Board (DSMB) has recommended that BioCardia continue its Phase I/II CardiALLO-HF trial as planned. This decision follows a review of 30-day safety data from participants in the trial's low-dose 20 million cell cohort, which showed no treatment-related adverse cardiac events or immune responses to the implanted allogeneic cells. With DSMB approval, BioCardia plans to expand the study by enrolling 39 additional participants across the U.S. The trial is designed to evaluate the safety and efficacy of mesenchymal stromal/stem cells (MSCs) in treating heart failure.
Heart Failure Overview
Heart failure, sometimes called congestive heart failure, is a progressive, chronic illness in which the heart muscle cannot pump enough blood to meet the body's oxygen and blood requirements. Both the left and right sides of your heart, or both at once, may be affected by heart failure.
Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:
• TN-301: Tenaya Therapeutics
• Invimestrocel: Athersys
• TT-00920: TransThera Biosciences
• JK-07: SalubrisBio
• IONIS AGT LRx: Ionis Pharmaceuticals
• APD418: Arena Pharmaceuticals
• PL-3994: Palatin Technologies
• Finerenone: Bayer HealthCare Pharmaceuticals
• Tirzepatide: Eli Lilly and Company
Heart Failure Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Heart Failure Molecule Type
Heart Failure Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Heart Failure Pipeline Therapeutics Assessment
• Heart Failure Assessment by Product Type
• Heart Failure By Stage and Product Type
• Heart Failure Assessment by Route of Administration
• Heart Failure By Stage and Route of Administration
• Heart Failure Assessment by Molecule Type
• Heart Failure by Stage and Molecule Type
DelveInsight's Heart Failure Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Heart Failure Therapeutics Market include:
Key companies developing therapies for Heart Failure are - Abbott Laboratories, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Jarvik Heart Inc., Lepu Medical Technology (Beijing)Co.,Ltd., Magenta Medical Ltd, MEDICO S.R.L., Medtronic PLC, Oscor, Inc., OSYPKA MEDICAL, Shree Pacetronix Ltd, and others.
Heart Failure Pipeline Analysis:
The Heart Failure pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
• Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Heart Failure drugs and therapies
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart Failure Pipeline Market Drivers
• Alongside these drug launches, a new therapeutic strategy is being explored, prevalence of chronic heart failure on the rise, strong collaboration between main stakeholders of therapeutic innovation: scientific community, industry and regulatory agencies are some of the important factors that are fueling the Heart Failure Market.
Heart Failure Pipeline Market Barriers
• However, true surrogate marker for mortality in heart failure (HF) remains elusive, high cost of approved therapies, transition of a clinical HFrEF project from one stage of development to the next is still associated with considerable development risk and other factors are creating obstacles in the Heart Failure Market growth.
Scope of Heart Failure Pipeline Drug Insight
• Coverage: Global
• Key Heart Failure Companies: Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others
• Key Heart Failure Therapies: TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others
• Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
• Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heart Failure Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight here
News-ID: 4148578 • Views: …
More Releases from DelveInsight Business Research
Global Injectable Drug Delivery Devices Market to grow at a CAGR of 11.26% by 20 …
According to DelveInsight's analysis, The growth in demand for injectable drug delivery devices is largely driven by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders, the increasing adoption of self-injectors, expansion of the biologics and biosimilars market, the growing emphasis on patient compliance with treatments, and continuous innovations and technological advancements in the field.
DelveInsight's "Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2030" report…
Abdominal Aortic Aneurysm Market Expected to Gain Momentum Through 2034, Accordi …
DelveInsight's "Abdominal Aortic Aneurysm Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Abdominal Aortic Aneurysm, historical and forecasted epidemiology as well as the Abdominal Aortic Aneurysm market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Abdominal Aortic Aneurysm market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Abdominal Aortic Aneurysm…
Focal Segmental Glomerulosclerosis Market to Witness Promising Upswing by 2034, …
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market…
Frontotemporal Dementia Pipeline 2025: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Frontotemporal Dementia pipeline constitutes 15+ key companies continuously working towards developing 20+ Frontotemporal Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Frontotemporal Dementia Pipeline Insight, 2025 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.
The Frontotemporal…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
